参考文献/References:
[1] 林苏,刘懿.胃肠道间质瘤.国外医学·消化系疾病分册,2005,25(1):25-28.
[2] Miettinen M. Sobin LH, Lasota J. Gastrointestinal stromal tumors of the stomach:a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up. Am J Surg Pathol, 2005, 29(1):52-68.
[3] 邓伟雄,庄思敏,温东东,等.恶性胃肠道间质瘤25例诊治体会.广东医学,2004,25(4):432-433.
[4] Mazur MI, Clark HB. Gastric stromal tumors. Reappraisal of histogenesis. Am J Surg Pathol, 1983, 7(6):507-519.
[5] Miettinen M, Lasota J. Gastrointestinal stromal tumors-deftnition, clinical, histological, immunohistochemical, and molecular genetic features and diferential diagnosis. Virchows Arch, 2001, 438(1):1-12.
[6] Corless CL, Fletcher JA, Heinrich MC. Biology of gastrointestinal stromal tumors. J Clin Oncol, 2004, 22(18):3813-3825.
[7] Mignon F, Julié C, Izzillo R, et al. Imaging features of gastric stromal tumors:radiologic-pathologic correlation. Report of 4 cases. J Radiol, 2000, 81(8):874-881.
[8] 王冬青,曾蒙苏,饶圣祥,等.CT在胃肠道间质瘤诊断及随访中的价值.实用放射学杂志,2006,22(6):695-697.
[9] Ji F,Wang ZW, Wang LJ, et al. Clinicopathological characteristics of gastrointestinal mesenchymal tumors and diagnostic value of endoscopic uhrasonography. J Gastroenterol Hepatol, 2008, 23(8pt z):e318-e324.
[10] 宋建兵,汤继军,郭应兴,等.影像学检查对胃肠道间质瘤诊断价值的临床分析.实用放射学杂志,2006,22(7):832-834.
[11] Kamiyama Y, Aihara R, Nakabayashi T, et al. 18F-fluorodeoxyglucose positron emission tomography:useful technique for predicting malignant potential of gastrointestinal stromal tumors. World J Surg, 2005, 29(11):1429-1435.
[12] Steigen SE, Bjerkehagen B, Haugland HK, et al. Diagnostic and prognostic markers for gastrointestinal stromal tumors in Norway. Mod Pathol, 2008, 21(1):46-53.
[13] Wong NA, Young R, Malcomson RD, et al. Prognostic indicators for gastrointestinal stromal tumors:a clinicopathological and immunohistochemical study of 108 resected cases of the stomach.Histopathology, 2003, 43(2):118-126.
[14] 周立群,陈剑秋.胃肠道间质瘤的诊治研究进展.医学综述,2008,14(11):1467-1468.
[15] 万德森,伍小军,梁小曼,等.胃肠道间质瘤的外科治疗.中华胃肠外科杂志,2003,6(5):288-291.
[16] Demetri GD, van Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med, 2002, 347(7):472-480.
[17] Nishida T, Shirao K, Sawaki A, et al. Efficacy and safety profile of imatinib mesylate (ST1571) in Japanese patients with advaneed gastrointestinal stromal tumors:a phase II study(ST1871B1202). Int J Clin Oncol, 2008, 13(3):244-251.
[18] Antoch G, Kanja J, Bauer S, et al. Comparison of PET, CT, and dual-modality PET/CT imaging for monitoring of imatinib (STI571) therapy in patients with gastrointestinal stromal tumors. J Nucl Med, 2004, 45(3):357-365.
[19] Goerres GW, Stupp R, Barghouth G, et al. The value of PET, CT and in-line PET/CT in patients with gastrointestinal stromal tumours:long-term outcome of treatment with imatinib mesylate. Eur J Nucl Med Mol Imaging, 2005, 32(2):153-162.
[20] 张孝平,管建国.甲磺酸伊马替尼在胃肠道间质瘤中的应用.基础医学论坛,2007,11(9):456-457.
[21] Trent JC, Ramdas L, Dupart J, et al. Early effects of imatinib mesylate on the expression of insulin-like growth factor binding protein-3 and positron emission tomography in patients with gastrointestinal stromal tumor. Cancer, 2006, 107(8):1898-1908.
[22] Stroobants S, Goeminne J, Seegers M, et al. 18FDG-positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). Eur J Cancer, 2003, 39(14):2012-2020.
[23] Heinicke T, Wardelmann E, Sauerbnlch T, et al. Very early detection of response to imatinib mesylate therapy of gastrointestinal stromal tumors using 18fluoro-deoxyglucose-positron emission tomography. Anticancer Res, 2005, 25(6C):4591-4594.
[24] 万德森.胃肠道间质瘤术后复发转移的治疗.肿瘤研究与临床,2006,18(8):524-526.
[25] DeMatteo RP, Lewis JJ, Leung D, et al. Two hundred gastrointestinal stromal tumors:recurrence patterns and prognostic factors for survival. Ann Surg, 2000, 231(1):51-58.
[26] Sobhani I, Tiret E, Lebtahi R, et al. Early detection of recurrence by 18FDG-PET in the follow-up of patients with colorectal cancer. Br J Cancer, 2008, 98(5):875-880.
相似文献/References:
[1]何燕,苏晋,郑晓霞,等.P-糖蛋白抑制剂在PET显像中的应用研究[J].国际放射医学核医学杂志,2016,40(1):1.[doi:10.3760/cma.j.issn.1673-4114.2016.01.001]
He Yan,Su Jin,ZhengXiaoxia,et al.Developing P-glycoprotein inhibitor marked by PET[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):1.[doi:10.3760/cma.j.issn.1673-4114.2016.01.001]
[2]许飞,刘建军,黄钢,等.PET乏氧显像在预测肿瘤乏氧及指导临床治疗中的应用进展[J].国际放射医学核医学杂志,2016,40(1):35.[doi:10.3760/cma.j.issn.1673-4114.2016.01.008]
Xu Fei,Liu Jianjun,Huang Gang,et al.The application of hypoxia imaging with PET in predicting tumor hypoxia and guiding clinical therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):35.[doi:10.3760/cma.j.issn.1673-4114.2016.01.008]
[3]胡伟,赵军.小胶质细胞在AD炎性机制中的作用及其常见PET显像剂的应用进展[J].国际放射医学核医学杂志,2016,40(1):44.[doi:10.3760/cma.j.issn.1673-4114.2016.01.009]
Hu Wei,Zhao Jun.Microglia’s Alzheimer disease inflammatory mechanisms and progress of its common application in PET imaging agents[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):44.[doi:10.3760/cma.j.issn.1673-4114.2016.01.009]
[4]张莹莹,王振光,孔艳.PET/CT显像在肺间质纤维化中的应用进展[J].国际放射医学核医学杂志,2016,40(1):55.[doi:10.3760/cma.j.issn.1673-4114.2016.01.011]
Zhang Yingying,Wang Zhenguang,Kong Yan.Application advancement on PET/CT in pulmonary interstitial fibrosis[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):55.[doi:10.3760/cma.j.issn.1673-4114.2016.01.011]
[5]李海峰,张晓军,李云钢,等.国产模块LOOP环改良法合成11C-蛋氨酸[J].国际放射医学核医学杂志,2016,40(2):106.[doi:10.3760/cma.j.issn.1673-4114.2016.02.004]
Li Haifeng,Zhang Xiaojun,Li Yungang,et al.Synthesis of 11C-methionine on home-made module by the improved LOOP method[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):106.[doi:10.3760/cma.j.issn.1673-4114.2016.02.004]
[6]史文杰,孟召伟,谭建.基于Deauville标准探讨18F-FDG PET/CT在霍奇金淋巴瘤复发诊断中的应用价值[J].国际放射医学核医学杂志,2016,40(2):120.[doi:10.3760/cma.j.issn.1673-4114.2016.02.007]
Shi Wenjie,Meng Zhaowei,Tan Jian.Value of 18F-FDG PET/CT on diagnosis of Hodgkin lymphoma recurrence using Deauville criterion[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):120.[doi:10.3760/cma.j.issn.1673-4114.2016.02.007]
[7]李海峰,张晓军,张锦明.多巴胺转运蛋白显像剂11C-β-CFT在帕金森病中的应用研究[J].国际放射医学核医学杂志,2016,40(3):218.[doi:10.3760/cma.j.issn.1673-4114.2016.03.011]
Li Haifeng,Zhang Xiaojun,Zhang Jinming.Review of the use of dopamine transporter imaging agent 11C-β-CFT for diagnosing Parkinson disease[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):218.[doi:10.3760/cma.j.issn.1673-4114.2016.03.011]
[8]尤阳,轩昂,张杰,等.淋巴瘤患者大脑静息葡萄糖代谢改变[J].国际放射医学核医学杂志,2016,40(4):255.[doi:10.3760/cma.j.issn.1673-4114.2016.04.003]
You Yang,Xuan Ang,Zhang Jie,et al.Changes in resting-state brain glucose metabolism in patients with lymphoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):255.[doi:10.3760/cma.j.issn.1673-4114.2016.04.003]
[9]王朋,崔邦平,代文莉,等.18F-FDG PET/CT在前列腺癌中的应用进展[J].国际放射医学核医学杂志,2016,40(4):277.[doi:10.3760/cma.j.issn.1673-4114.2016.04.008]
Wang Peng,Cui Bangping,Dai Wenli,et al.Progress in the application of 18F-FDG PET/CT in prostate cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):277.[doi:10.3760/cma.j.issn.1673-4114.2016.04.008]
[10]李菲,黄俊星,张俊.18F-FDG PET/CT在食管癌中的临床应用[J].国际放射医学核医学杂志,2016,40(4):282.[doi:10.3760/cma.j.issn.1673-4114.2016.04.009]
Li Fei,Huang Junxing,Zhang Jun.The clinical application of 18F-FDG PET/CT in esophageal cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):282.[doi:10.3760/cma.j.issn.1673-4114.2016.04.009]